BioWorld

June 5, 2009

Still No Winner in Acute HAE; FDA Wants New Cinryze Trial

Another runner has stumbled on a regulatory hurdle on the race to get the first acute hereditary angioedema (HAE) drug to market. (BioWorld Today) Read More

With No Partner, Anadys Cuts Jobs and Raises $17M

New Study Describes Immune Mechanisms of Anaphylaxis

Experts: Health Reform Must Address Diabetes

Adolor Cuts Staff 28% to Focus on Entereg

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...